‏إظهار الرسائل ذات التسميات treatment. إظهار كافة الرسائل
‏إظهار الرسائل ذات التسميات treatment. إظهار كافة الرسائل

الأحد، 26 أغسطس 2012

Risk of preterm birth after treatment for cervical intraepithelial neoplasia among women attending colposcopy in England: retrospective-prospective cohort study

Risk of preterm birth after treatment for cervical intraepithelial neoplasia among women attending colposcopy in England: retrospective-prospective cohort study | BMJ

Menu

Search BMJ Group Search BMJ Group   Journals Jobs Education Decision support Quality improvement Community

BMJ Group

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients

About BMJ Group Customer Service Subscriptions & Sales Working for BMJ Group BMJ Media Centre BMJ Group Awards Advertising & Sponsorship Rights & Licensing Affinity & Society Publishing Online learning BMJ Learning High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications BMJ Masterclasses BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

BMJ Learning BMJ Portfolio BMJ Masterclasses Clinical Leadership Programme Diabetes Qualifications and Courses onExamination Decision support and clinical reference BMJ Evidence Centre

The BMJ Evidence Centre builds evidence into practice, to support improvements in the consistency and quality of health care.

Best Practice Clinical Evidence Evidence Updates Best Health Action Sets Informatica Systems Informatica Systems delivers performance management systems and innovative software solutions to primary care. Learn more

Audit + Contract + Health Checks FrontDesk BMJ Quality

The latest news, research, events, opinion and guidance related to quality and safety in health care.

The 2013 event will take place in London from 16th- 19th April 2013. Find out more

BMJ Quality BMJ Quality and Safety International Forum on Quality and Safety in Healthcare BMJ

The flagship general medical journal, published since 1840, updated daily online, weekly in print and on the iPad.

BMJ BMJ Journals

BMJ Journals division publishes over 40 journals across a broad range of specialties.

BMJ Journals studentBMJ

An international medical journal written for students by students.

Student BMJ Jobs BMJ Careers

BMJ Careers makes it easy for you to find the right job with the latest healthcare vacancies, upcoming careers fairs, advice on choosing the right specialty, pay and working conditions.

19-20 October 2012 at the Business Design Centre in Islington, London. Register here

BMJ Careers Jobs and vacancies at BMJ Group BMJ Careers Fair Community

Join the discussions on our community site doc2doc or our social pages

... by doctors, for doctors, for patients
We are open for entries!

doc2doc Follow BMJ Group on Twitter BMJ Group on Facebook BMJ Group Awards Subscribe My account

Update my details

Manage my emails

BMA Members Sign in Username: * Password: * Forgot your sign in details?BMA membersAthens or your organisation BMJ Helping doctors make better decisions Search bmj.com:   Advanced search Home Research Education News Comment Multimedia Specialties Archive Search all BMJ research articles:   From18401841184218431844184518461847184818491850185118521853185418551856185718581859186018611862186318641865186618671868186918701871187218731874187518761877187818791880188118821883188418851886188718881889189018911892189318941895189618971898189919001901190219031904190519061907190819091910191119121913191419151916191719181919192019211922192319241925192619271928192919301931193219331934193519361937193819391940194119421943194419451946194719481949195019511952195319541955195619571958195919601961196219631964196519661967196819691970197119721973197419751976197719781979198019811982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012JanFebMarAprMayJunJulAugSepOctNovDec To18401841184218431844184518461847184818491850185118521853185418551856185718581859186018611862186318641865186618671868186918701871187218731874187518761877187818791880188118821883188418851886188718881889189018911892189318941895189618971898189919001901190219031904190519061907190819091910191119121913191419151916191719181919192019211922192319241925192619271928192919301931193219331934193519361937193819391940194119421943194419451946194719481949195019511952195319541955195619571958195919601961196219631964196519661967196819691970197119721973197419751976197719781979198019811982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012JanFebMarAprMayJunJulAugSepOctNovDec Limit by AllResearchMethods and reporting Our online table of contents is updated at least twice each day. Read all articles published in the last 7 days. You can use bmj.com to help you with your continuing medical education. Find out about CME/CPD credits for BMJ articles Keep up to date with cardiology: Access the latest cardiovascular medicine resources from across BMJ Group. OPEN ACCESS: All research articles are freely available online, with no word limit. Find out more about the BMJ's open access policy. Submit your paper. Find out how study types differ in our How to read a paper section. The truth about sports drinks: Find out more about the joint BMJ and BBC Panorama investigation into the evidence base behind many health claims.

Research Risk of preterm birth after treatment for cervical intraepithelial neoplasia among women attending colposcopy in England: retrospective-prospective cohort study BMJ 2012; 345 doi: 10.1136/bmj.e5174 (Published 17 August 2012) Cite this as: BMJ 2012;345:e5174 Article Related content Read responses (1) Article metrics Alejandra Castanon, epidemiologist1, Peter Brocklehurst, professor of women’s health2, Heather Evans, consultant obstetrics and gynaecology3, Donald Peebles, professor of maternal and fetal medicine2, Naveena Singh, consultant histopathologist4, Patrick Walker, consultant obstetrics and gynaecology3, Julietta Patnick, director5, Peter Sasieni, professor of cancer epidemiology and biostatistics1 for the PaCT Study Group
1Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London EC1M 6BQ, UK
2Institute for Women’s Health UCL, London, UK
3Department of Gynaecology, Royal Free Hampstead NHS Trust, London, UK
4Division of Cellular Pathology, Barts Health NHS Trust, London
5NHS Cancer Screening Programmes, Sheffield, UKCorrespondence to: P Sasieni p.sasieni{at}qmul.ac.ukAccepted 23 July 2012AbstractObjective To explore the association between preterm delivery and treatment at colposcopy.

Design Retrospective-prospective cohort study using record linkage.

Setting 12 National Health Service hospitals in England.

Participants Women who had a cervical histology sample taken between 1987 and 2009. These women were linked by hospital episode statistics to hospital obstetric records between 1998 and 2009 for the whole of England to identify singleton live births between 20-43 gestational weeks before or after cervical histology.

Main outcome measures Proportion of preterm births (<37 weeks); the relative risk for the strength of association between preterm births and treatment for cervical intraepithelial neoplasia.

Results 18?441 singleton births occurred: 4176 before histology and 14?265 after histology. Of the singleton births after histology, 9.0% (n=1284) were preterm compared with 6.7% of all births in England over the same period (excess risk 2.3 per 100 births, 95% confidence interval 1.8% to 2.8%). Among first births after histology, the adjusted relative risk associated with previous treatment was 1.19 (95% confidence interval 1.01 to 1.41); among first births before histology the relative risk associated with subsequent treatment was 1.47 (1.05 to 2.05). Combining these, the relative risk associated with treatment adjusted for timing relative to histology was 0.91 (0.66 to 1.26) corresponding to an absolute difference of -0.25 (-2.61 to 2.11) per 100 singleton births. Among 372 women who gave birth both before and after treatment, there were 30 preterm births after treatment and 32 before treatment (relative risk 0.94, 0.62 to 1.43).

Conclusion The risk of preterm delivery in women treated by colposcopy in England was substantially less than that in many other studies, predominantly from Nordic countries. The increased risk may be a consequence of confounding and not caused by treatment. Although this study is reassuring for large loop excision of the transformation zone overall, it is possible that deep conisation or repeated treatment leads to an increased risk of preterm delivery.

IntroductionScreening for cervical cancer aims to detect and treat cancer precursors (cervical intraepithelial neoplasia) before progression to invasive cancer. Women with abnormal cytology are referred to colposcopy for further assessment. In the United Kingdom, most of these women will either have no procedure (and be discharged) or have a punch biopsy sample taken at their first colposcopy appointment to confirm the presence or absence of disease, whereas others (particularly those with high grade cytological abnormalities) may be offered excisional treatment at the first visit.1 Those with a histological sample showing high grade cervical intraepithelial neoplasia are commonly treated by large loop excision of the transformation zone (LLETZ). Other less common types of fertility preserving treatment include laser conisation, cold knife excision, cold coagulation, and other ablative treatments.2

In recent years several studies have linked treatment for cervical intraepithelial neoplasia with a higher risk of subsequent preterm delivery (before 37 completed weeks of gestation). Preterm infants are associated with substantial emotional and economic costs to their families and communities and have a disproportionate impact on health service utilisation. In 2006 a widely cited meta-analysis of 27 included studies found that large loop excision of the transformation zone was associated with preterm delivery, low birth weight, and preterm premature rupture of membranes.3 Since then several studies have been published on this subject. The largest to date, a Norwegian record linkage study of 57?136 births before treatment and 15?108 after treatment, found the proportion of preterm deliveries in each group, respectively, to be 6.7% and 17.2%.4 Few studies are from the United Kingdom and those that are tend to be generally small5 6 7 8 9 and do not confirm the strong association between treatment and subsequent preterm delivery found elsewhere. Colposcopy and treatment of cervical intraepithelial neoplasia in England is quality assured by the National Health Service cervical screening programme and self regulated by the British Society for Colposcopy and Cervical Pathology.10 It is possible that the results reported internationally are not representative of large loop excision of the transformation zone as carried out by specially trained colposcopists working to detailed clinical guidelines.

We explored the association between preterm delivery and treatment at colposcopy by comparing three populations: external (population of England), internal (within the cohort), and within individual women. We reasoned that although excisional treatment might result in a subsequent preterm delivery, punch biopsy is too small to have such a causal role. Furthermore, by definition treatment cannot affect the outcome of a birth that occurred before that treatment. In our analyses we adjusted for any increased risk associated with a history of cervical intraepithelial neoplasia and focused on the association with the treatment itself.

MethodsWe identified women from clinical records in 12 NHS hospitals as having had a cervical histology sample taken (by a punch biopsy at colposcopy or excisional treatment, or both) between January 1987 and December 2009. Hospitals included in the study responded to an invitation for participation in a letter posted on the British Society for Colposcopy and Cervical Pathology website and sent to the hospitals’ mailing lists. A prerequisite for participation was that the units had over 350 new referrals a year and support from their local research and development office. Of units that expressed an interest we selected the largest (>550 new referrals a year) in each region of the country to ensure representation from all of England. Three selected units could not obtain local ethical approval in time and we substituted these with others in regions already represented in the study and one with fewer than 300 referrals a year.

For each woman, we obtained the date of the first and last histological sample recorded in the clinic and requested the most severe procedure (that is, whether it was a punch biopsy or material from excisional treatment) carried out at these visits. Thus we split our cohort into three groups: women with a punch biopsy, women with excisional treatment, and women with a record of cervical histology but missing treatment status. We followed these women prospectively (through retrospective linkage) for gestational age of subsequent births, and retrospectively for gestational age of previous births.

To identify live births whether before or after the histological sample had been obtained, we linked women by their NHS number and date of birth to hospital episode statistics of inpatient obstetric records between April 1998 and April 2010 for the whole of England. The NHS number is a unique identifier issued when a birth is registered or when an individual first registers with an NHS general practitioner. Hospital episode statistics is a data warehouse containing details of all admissions to NHS hospitals in England, including private patients treated in NHS hospitals.11 From hospital episode statistics records we obtained information on month and year of delivery, gestational age, birth weight, onset of delivery, mode of delivery, resuscitation method, number of previous pregnancies, duration of stay in hospital, and any inpatient diagnosis or operation recorded for the mother.

National comparisonTo obtain the proportion of preterm deliveries in the population for the study period we extracted and pooled NHS maternity statistics12 (published by hospital episode statistics) from 2000-01 to 2009-10. We were unable to find data before April 2000 and would have considered age standardised proportions, but the published reports of gestational age by maternal age did not separate singleton from multiple births as we have done here.13

We considered only births with a known gestational age and that were between 20 and 43 weeks. As best practice indicates that pregnancies should not exceed the 42nd gestational week, we excluded infants born at gestational ages greater than 43 weeks to avoid any inaccuracies of gestational ages over 43 weeks. Because of concerns over accuracy we also excluded births with a recorded gestational age under 20 weeks (599 nationally and 16 in our cohort). We excluded multiple births (twins and triplets). The same exclusions applied to the NHS maternity statistics.

To avoid having to adjust for clustering of preterm deliveries within individuals we limited the internal analysis to the first pregnancy recorded in our cohort data during the 11 year period between 1998 and 2010. We also excluded antepartum stillbirths or stillbirths of indeterminate timing (n=216) on the basis that we could not establish whether preterm delivery was induced as a result of the death of the fetus or vice versa. Supplementary table A1 shows the distribution of births in the cohort by parity, whether the mother was treated before or after delivery, and type of treatment received.

Statistical analysisTo obtain relative risks and 95% confidence intervals for the difference in proportions of births that were preterm compared with those that were term, we used relative risk regression (an alternative to logistic regression for cohort studies) using the glm command in Stata. We adjusted the relative risks for maternal age at delivery (<25, 25-34, >34), parity (0, 1, 2, =3), and study site. To determine parity in the cohort we used the number of previous pregnancies recorded by hospital episode statistics, except where a birth was found in the dataset that was not reflected in the parity field. For completeness we also report the results of risk differences, also estimated using the glm command in Stata. P values cited are for the Pearson’s ?2 test for the difference between proportions or for the likelihood ratio test in other situations.

We compared singleton births using three groups. The first groups (external comparisons) were relative to NHS maternity statistics for the whole of England. In the external comparisons we compared all births in the cohort, all births after histology, and births after treatment with all births in England. For the internal comparisons we considered only first births in the dataset and compared (a) births after histology with those before histology, and births after treatment with each of (b) births before treatment, (c) births after histology in untreated women, and (d) births before histology in untreated women adjusting for disease history. The within woman comparison was between the last birth before colposcopy and the first after colposcopy in a given woman. We considered all women with births both before and after colposcopy and the subset of treated women. We also considered the ratio of the after to before effect in treated women relative to the effect in untreated women (that is, with biopsy only). The confidence interval for the women with biopsy only was obtained by treating the two relative risks (within treated women and within untreated women) as independent. In the within woman analyses we did not adjust for parity or maternal age. For dealing with the question of the effect of treatment on preterm delivery, we considered the most relevant analyses to be for the external comparison, births after treatment; for the internal comparison, births after treatment compared with births before histology adjusting for disease history; and for the within woman comparison, all treated women with births before and after treatment.

The risk ratio comparing births after treatment with births before histology adjusting for disease history is obtained from the interaction term (1 for post-treatment, 0 otherwise) in a generalised linear model with an effect for treatment (1 for treated or subsequently treated, 0 otherwise) and an effect for timing (1 for post-histology, 0 otherwise). In the absence of other adjustments, it is simply the ratio of the relative risks of preterm delivery in (a) births after treatment compared with births after biopsy only to (b) births before treatment compared with birth before biopsy only.

For comparison with published meta-analyses, we added our study to those in the published meta-analysis of 27 included studies to determine whether it differed significantly (taking into account the heterogeneity in earlier studies) using the metareg command in Stata. All analyses were done in Stata 11 (release 11.2. College Station, Texas).

ResultsParticipating hospitalsOn average, the 12 participating clinics were similar to the other 215 clinics in England for published data on colposcopy (see supplementary table A2). With one exception, the mean value of each data item in participating clinics was within the interquartile range of the other clinics. The one exception was the proportion of biopsy results reported within eight weeks, which was 83% in the study clinics but at least 86% in 75% of other clinics nationally. The clinics included in this study accounted for 8.5% of all patients having new colposcopy in England in 2005-06.1

CohortA total of 44?210 NHS numbers of women with data on cervical histology were submitted for linkage to hospital episode statistics, 81.3% (35?958 women) had at least one hospital admission between 1998 and 2009 and 46.8% (16?816/35?958) of those with a record had at least one birth recorded. A total of 26?897 births (in 16?816 women) were identified (fig 1?). Of these, 18?441 were singleton births with known gestational age between 20 and 43 gestational weeks, of which 1616 were preterm (20-36 weeks) and 471 were very preterm (20-32 weeks). Table 1? presents the proportion of births by maternal age at delivery, parity, timing relative to colposcopy, and procedure at colposcopy.

View larger version:In a new windowDownload as PowerPoint SlideFig 1 Flow of women through study

View this table:View PopupView InlineTable 1 Proportion of births by maternal age at delivery, parity, timing relative to colposcopy, and procedure at colposcopy

External comparison (population based)The average preterm delivery rate in England between 2000 and 2010 was 6.7% (34?153/510?660, fig 2?). The preterm rate varied from 6.9% in 2000 to 5.9% in 2009, with a minimum of 5.9% in 2009 and a maximum of 7.6% in 2004. Overall, the observed preterm rate in our cohort was 8.8% (1616/18?441), yielding an excess risk of preterm delivery of 2.08 per 100 singleton births (95% confidence interval 1.66% to 2.49%; P<0.001) and a relative risk of 1.31 (95% confidence interval 1.25 to 1.37) compared with the general population. The proportion of births after cervical histology that were preterm was 9.0% (1284/14?265), giving an excess risk of 2.31 per 100 births (1.84% to 2.79%) and a relative risk of 1.35 (1.28 to 1.42) compared with the general population. Similar results were observed for deliveries after treatment (9.4%, 449/4776, table 2?). This relative risk (1.41, 1.29 to 1.54) was significantly (P=0.03, even after allowing for heterogeneity in the meta-analysis) lower than the comparable result in a meta-analysis (1.97, 1.78 to 2.17).14 The proportion of preterm births after histology, however, varied widely by hospital (fig 2) from 6.2% (161/2608, Wirral University Teaching Hospital) to 15.6% (33/212, St Mary’s Hospital, Imperial College) (?211=66.07, P<0.001).

View larger version:In a new windowDownload as PowerPoint SlideFig 2 Proportion of preterm deliveries after colposcopy by study centre, overall, and compared with England

View this table:View PopupView InlineTable 2 Summary of analyses and results

Internal comparisonFor comparisons within the cohort only the first birth recorded in the dataset was included for each woman, and antepartum stillbirths and stillbirths of indeterminate timing were excluded. This left 12?937 births of which 1099 (8.5%) were preterm. Overall, 52.6% (n=578) of these preterm births had a gestational age of 35-36 weeks, 19.3% (n=212) at 33-34 weeks, 17.5% (n=192) at 29-32, and 10.6% (n=171) at 20-28 weeks. The mean maternal age at first recorded delivery (n=12?937) was 31 (interquartile range 27-34) years.

Among singleton births delivered after cervical histology, 8.9% (832/9368) were preterm compared with 7.5% (267/3569) of those delivered before the date of histology (table 2). The increase in risk of preterm delivery (adjusted by study site, parity, and maternal age at delivery) was significant (adjusted relative risk 1.32, 95% confidence interval 1.13 to 1.53). Figure 3? plots the relative risks for all 12 study sites: there was no evidence of heterogeneity between sites (?211=11.574, P=0.40).

View larger version:In a new windowDownload as PowerPoint SlideFig 3 Relative risk of preterm birth in women with a birth after compared with before colposcopy

The type of sample taken at colposcopy was recorded for 80.6% of births in the cohort (10?423 singleton births) including 77.8% (n=855) of preterm deliveries. Of those that had a delivery after colposcopy, the risk of preterm delivery in women who had a treatment was 9.1% (283/3095) compared with 8.3% (396/4770) in women who had a punch biopsy only (adjusted relative risk 1.19, 1.01 to 1.41). The absolute increased risk of preterm delivery after treatment when compared with a biopsy only adjusted for study site, parity, and maternal age was 1.5 per 100 births (0.1% to 2.9%).

The relative risks for treated versus punch biopsy were similar for births before the histological sample was taken (table 3?). Of births before histology, 7.8% (81/1045) of those in women who were subsequently treated were preterm compared with 6.3% (95/1513) in women who subsequently had a punch biopsy and no treatment (adjusted relative risk 1.31, 0.97 to 1.76, table 3). Thus the risk ratio comparing births after treatment with births before histology adjusting for disease history was 0.91 (95% confidence interval 0.66 to 1.26).

View this table:View PopupView InlineTable 3 Adjusted relative risks for association between cervical histology and preterm delivery

The proportion of births that were under 33 gestational weeks (see supplementary table A3) in those women who had a histology sample taken before birth was 2.8% (243/8779) compared with 2.0% (66/3368) in women who had a histology sample taken after birth (adjusted relative risk 1.60, 1.18 to 2.18). The adjusted relative risk in births after colposcopy comparing treatment with biopsy only was 1.23 (0.89 to 1.69). Further adjustment for disease history yielded a relative risk for delivery under 33 weeks of 0.81 (0.43 to 1.52).

Since the analysis was limited to the first recorded birth in each woman, the risk ratio (treated versus punch biopsy) was also examined and was different in second or subsequent births after colposcopy compared with first births after colposcopy. The adjusted relative risk for treatment in second and subsequent births after colposcopy was non-significantly (P=0.39) greater than for first births after colposcopy, but similar to that of the last birth before colposcopy (see supplementary table A4).

Within womanAn analysis was carried out restricted to women who had a birth both before and after a colposcopy (within woman comparison, table 2). For each woman the last birth before treatment and the first birth after treatment was only included. This left 1078 women. There were 80 (7.4%) preterm births before colposcopy and 98 (9.1%) after colposcopy (relative risk 1.23, 95% confidence interval 0.95 to 1.59, P=0.15). In 372 women with births both before and after treatment, there were 30 preterm births after treatment and 32 before treatment (the relative risk of preterm birth after treatment was 0.94, 0.62 to 1.43). In 501 women with births both before and after punch biopsy, the relative risk of preterm birth after a punch biopsy was 1.14 (0.77 to 1.66). The ratio of the risk ratios (of preterm birth after:before colposcopy) for treated compared with untreated (biopsy only) women was 0.82 (0.27 to 3.17, see supplementary table A5).

Since in general the risk of a preterm birth is greater in a first birth than in a second birth (8.8% v 7.6% in the study cohort, table 1), and given that most women who gave birth both before and after colposcopy had exactly one birth before colposcopy (so that that second births were compared with first births), the relative risk will have been underestimated. However, in women with at least two births the risk of preterm on first birth was less (8.1%), yielding a relative risk of 0.98 (0.85 to 1.13) for second birth compared with first birth in women with at least two births.

DiscussionIn this study of 18?441 singleton deliveries in women who had a cervical biopsy sample taken during colposcopy in England, the additional risk of a preterm birth over that in the general population was 2.1 per 100 singleton births, yielding a relative risk of 1.31. Comparing births in women within the cohort (table 2), the relative risk in women who previously had treatment (conisation, large loop excision of the transformation zone, loop excision) compared with those who only had a biopsy was 1.19. However, the relative risk of preterm delivery in women before colposcopy comparing those who subsequently had treatment with those who subsequently only had a biopsy was also greater than 1 (1.33). Consequently the risk ratio comparing births after treatment with births before histology adjusting for disease history was less than 1, with an upper limit of the 95% confidence interval of 1.26. Furthermore, in 372 women who gave birth both before and after treatment for cervical intraepithelial neoplasia, the number of births that were preterm was fewer after treatment than before (30 v 32).

Strengths and limitations of the studyIn considering causality in the absence of a randomised controlled trial, we took into account confounding by risk modifying factors and the temporality of cause and effect. We allowed for the possibility of general confounding: factors (such as smoking or ethnicity) that might predispose a woman to both abnormal cervical cytology and preterm births; confounding by disease severity—the possibility that factors (such as immune suppression) that make it more likely for a woman to have high grade disease (and be treated by cone excision) will also make her more likely to have a preterm birth; and disease causing prematurity—that the disease in itself (or factors that lead to its presentation) rather than its treatment makes a woman more likely to have a preterm birth. In our analyses we attempted to take into account all three possible sources of confounding. The first analyses included all singleton births in the cohort to ease comparison with published population statistics. Although we present the risk of preterm birth for both the whole cohort and births after treatment, we did not adjust for possible confounding. The internal analysis eliminates general confounding because all women by definition have had colposcopy. To exclude confounding by disease severity, we considered women with treatment and compared births after treatment with those before treatment. To exclude confounding owing to disease causing preterm delivery, we compared births after treatment with those after biopsy only. To take account of both disease severity and temporality, we calculated the ratio of these relative risks. This ratio was less than 1, suggesting that the associations observed in the other analyses could all result from confounding. Finally we took births before and after colposcopy in the same woman. Such an analysis is complicated by changing parity and maternal age, but the relative risk after treatment was less than 1. Additionally, the post-colposcopy relative risk in treated women was less than that in women who only had a punch biopsy (see supplementary table A5) suggesting that confounding has not artificially reduced the relative risk of treatment. However, for 19.4% of women we do not know the type of procedure carried out at colposcopy. This could have an important impact on the estimates comparing treated with untreated women if, for instance, those with an unknown procedure were more likely both to be treated and to subsequently have a preterm birth. This problem will be further investigated in phase 2 of this study (a nested case-control study).

The results in this paper depend on the quality of birth data submitted by participating clinics (NHS trusts) to hospital episode statistics. The proportion of preterm births will also be affected by the population served by the clinic. For example, Whipps Cross Hospital serves a community with a high proportion of ethnic minority groups, whereas St Mary’s Hospital is a referral centre for high risk pregnancies from across London.

There is also a question as to how representative the colposcopy units in this study are of colposcopy done across England. The 12 participating units included both teaching and non-teaching hospitals but were primarily self selected. We therefore investigated the extent to which they seemed to be representative of all colposcopy clinics in England on the basis of published data. Comparing nationally collected statistics from the clinics in this study with the other (n=215) clinics in England showed that in terms of these statistics, the clinics in this study were not atypical of the rest of the country. Colposcopy clinics in England are audited every three years, as are all colposcopists to maintain their membership with the British Society for Colposcopy and Cervical Pathology. Thus the standard of colposcopy in England is likely to be more homogeneous than in many countries. Even if treatment in smaller centres resulted in a greater risk of preterm delivery, we believe that this study (with 8.5% of all new patients in England) is representative of most colposcopy in England.

We tried to minimise biases in this study by restricting the analysis to the first live singleton birth recorded for each women and by adjusting the relative risk by study centre. Additionally, the design of the study avoided recall and selection bias. However, we had no information on risk modifying factors such as ethnicity or smoking, nor did we have any detailed information on treatment received at colposcopy.

Comparison with other studiesThis is the largest study of preterm delivery in women with cytological abnormalities in the United Kingdom. A meta-analysis including 30 cohort studies in total found that the type of comparison group was important in determining the relative risk of preterm delivery.14 When the comparison group was external (such as the general population) the relative risk of preterm delivery was 1.97 (95% confidence interval 1.78 to 2.17). Similarly, when the comparison group was internal (comparing births after treatment with those before treatment), the relative risk was 1.96 (1.46 to 2.64). However, when the analysis was carried out within a cohort of women with cytological abnormalities comparing treated with untreated women, the relative risk was 1.25 (0.98 to 1.58). Three studies from Nordic countries obtained relative risks between 1.8 and 2.8 (all except one not included in the meta-analysis). Of the excluded studies, a large study from Norway found a relative risk of 2.13 (95% confidence interval 2.06 to 2.20) comparing (all not just singleton) births after treatment with births before treatment, but reported a declining relative risk during the study period.4 The absolute risk was 17.2% (in 15?108 births after treatment). Our preterm risk in treated women is clearly less. A study from Denmark had a relative risk of 2.8 (95% confidence interval 2.3 to 3.5) compared with an external control group.15 The same study also provided a within woman odds ratio of 2.8 (95% confidence interval 1.0 to10.0) as did a study from Finland (1.8, 95% confidence interval 1.04 to 3.21).16

The relative risk of preterm delivery after treatment observed in this study compared with the population as a whole is substantially (and significantly) less than that found in the studies included in the Bruinsma meta-analysis.14 Additionally, our internal analyses tend not to support the hypothesis that treatment increases the risk of preterm delivery, by a factor of about 1.7 to 2.0; the analysis that adjusts for both the timing of the delivery relative to colposcopy and whether there was treatment or just a punch biopsy gives a relative risk of 0.91 (95% confidence interval 0.66 to 1.26) for births subsequent to treatment.

Several studies have suggested that it is the amount of tissue removed from the cervix that produces the excess risk, not the procedure itself.17 18 19 It is possible that owing to the quality assurance of the colposcopy programme in England through both the cervical screening programme and the British Society for Colposcopy and Cervical Pathology, tissue removed during colposcopy is kept to a minimum and this could explain the smaller relative risks that we observed. This might be particularly relevant in the self selected colposcopy units in this study. We are currently undergoing phase 2 of this study in which we will attempt to obtain detailed colposcopy and pathology information on all women with a preterm delivery and a sample of women with a term delivery in this cohort. In particular, we are recording the measurements of the tissue excised and whether the woman was treated more than once. It seems likely that removal or destruction of a large amount of tissue may increase the risk of subsequent preterm delivery more than is seen on average.

Conclusions and policy implicationsThe results presented here are encouraging. Accepting the limitations of this study, women treated within the NHS cervical screening programme and particularly those treated in large colposcopy units should be reassured that, in this study of 44?000 women having colposcopy including 14?265 singleton births after colposcopy, the risk of a birth being preterm was 9.0% and only slightly greater than the risk in the general population. Phase 2 of this study should strengthen the results presented here and provide information on the risk associated with the depth of cervical tissue removed.

What is already known on this topicMost studies of preterm delivery after large loop excision of the transformation zone found that treatment was associated with increased risk

An influential meta-analysis (27 studies) found a relative risk of 1.70 (95% confidence interval 1.24 to 2.35)

Subsequent large studies from Nordic countries estimated the relative risk to be between 1.8 and 2.8

What this study addsAfter adjusting for confounding, the increased risk of preterm delivery in births after treatment for cervical intraepithelial neoplasia ceases to exist

There is only a small chance (2.5%) that the risk of preterm delivery is increased by more than 3.5 per 100 births in women treated in England

The relative risk here is significantly less than reported previously possibly because colposcopy treatment is quality assured

NotesCite this as: BMJ 2012;345:e5174

FootnotesMembers of the PaCT Study Group were responsible for the collection of data included in this study. N Gul and A Miles (Wirral University Teaching Hospital), A Hollingworth and R Wuntakal (Whipps Cross University Hospital London), N Singh and A Parberry (Barts and the London NHS Trust), J Palmer (Royal Hallamshire Hospital, Sheffield), N Das and L Russ (Royal Cornwall Hospital), N Wood and S Preston (Royal Preston Hospital Lancashire), M Hannemann and D Fuller (Royal Devon and Exeter NHS Foundation Trust), K Lincoln and P Rolland (The James Cook University Hospital, South Tees), S Ghaem-Maghami and P Soutter (Hammersmith Hospital, Imperial College), R Hutson (St James University Hospital, Leeds), P Senguita and J Dent (North Durham County and Darlington Trust), and D Lyons (St Mary’s Hospital, Imperial College).

Contributors: PS analysed the data and designed the database. He is the guarantor of the study and therefore accepts full responsibility for the work and the conduct of the study, had access to the data, and controlled the decision to publish. AC collated and analysed the data. All authors designed and established the study, wrote the paper, and approved the final version.

Funding: This manuscript presents independent research funded by the National Institute for Health Research (NIHR) under its research for patient benefit programme (No PB-PG-1208-16187). The views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR, or the Department of Health.

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; and no other relationships or activities that could appear to have influenced the submitted work.

Ethical approval: This study was approved by the Brompton, Harefield, and NHLI research ethics committee, Charing Cross Hospital, London (No 09/H0708/65).

Data sharing: The statistical code is available from the corresponding author at p.sasieni{at}qmul.ac.uk.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.

References?Lancucki L, ed. Cervical screening programme, England: 2005-06. NHS Information Centre, 2006. ?Luesley DLS, ed. NHS cervical screening programme. Colposcopy and programme management. Guidelines for the NHS cervical screening programme. NHS Information Centre, 2004.?Kyrgiou M, Koliopoulos G, Martin-Hirsch PL, Arbyn M, Prendiville W. Obstetric outcome after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet2006;367:489-98.OpenUrlCrossRefMedlineWeb of Science?Albrechtsen S, Rasmussen S, Thoresen S, Irgens LM, Iversen OE. Pregnancy outcome in women before and after cervical conisation: population based cohort study. BMJ2008;337:a1343.OpenUrlFREE Full Text?Reilly R, Paranjothy S, Beer H, Brooks C, Fielder H, Lyons R. Birth outcomes following treatment for precancerous changes to the cervix: a population-based record linkage study. BJOG2012;119:236-44.OpenUrlCrossRefMedline?Cruickshank M, Flannelly G, Campbell DM. Fertility and pregnancy outcome following large loop excision of the cervical transformation zone. Br J Obstet Gynaecol1995;102:467-70.OpenUrlMedlineWeb of Science?Shanbhag S, Clark H, Timmaraju V, Bhattacharya S, Cruickshank M. Pregnancy outcome after treatment for cervical intraepithelial neoplasia. Obstet Gynecol2009;114:727-35.OpenUrlCrossRefMedlineWeb of Science?Haffenden DK, Bigrigg A, Codling BW, Read MD. Pregnancy following large loop excision of the transformation zone. Br J Obstet Gynaecol1993;100:1059-60.OpenUrlMedlineWeb of Science?Tan L, Pepera E, Haloob RK. The outcome of pregnancy after large loop excision of the transformation zone of the cervix. J Obstet Gynaecol2004;24:25-7.OpenUrlCrossRefMedline?British Society for Colposcopy and Cervical Pathology. Constitution. BSCCP, 1975.?HES Online. What is HES? 2005-2007. 2011. www.hesonline.nhs.uk/Ease/servlet/ContentServer?siteID=1937&categoryID=456>.?NHS Information Centre. NHS maternity statistics, 2000-2010. 2010. www.ic.nhs.uk/pubs.?Office for National Statistics. Gestation-specific infant mortality in England and Wales, 2009. www.ons.gov.uk/ons/rel/child-health/gestation-specific-infant-mortality-in-england-and-wales/2009/index.html.?Bruinsma FJ, Quinn MA. The risk of preterm birth following treatment for precancerous changes in the cervix: a systematic review and meta-analysis. BJOG2011;118:1031-41.OpenUrlCrossRefMedline?Ortoft G, Henriksen T, Hansen E, Petersen L. After conisation of the cervix, the perinatal mortality as a result of preterm delivery increases in subsequent pregnancy. BJOG2010;117:258-67.OpenUrlCrossRefMedline?Jakobsson M, Gissler M, Paavonen J, Tapper AM. Loop electrosurgical excision procedure and the risk for preterm birth. Obstet Gynecol2009;114:504-10.OpenUrlCrossRefMedlineWeb of Science?Noehr B, Jensen A, Frederiksen K, Tabor A, Kjaer SK. Loop electrosurgical excision of the cervix and subsequent risk for spontaneous preterm delivery: a population-based study of singleton deliveries during a 9-year period. Am J Obstet Gynecol2009;201:33,e1-6.OpenUrlMedline?Acharya G, Kjeldberg I, Hansen SM, Sorheim N, Jacobsen BK, Maltau JM. Pregnancy outcome after loop electrosurgical excision procedure for the management of cervical intraepithelial neoplasia. Arch Gynecol Obstet2005;272:109-12.OpenUrlCrossRefMedline?Sadler L, Saftlas A, Wang W, Exeter M, Whittaker J, McCowan L. Treatment for cervical intraepithelial neoplasia and risk of preterm delivery. JAMA2004;291:2100-6.OpenUrlCrossRefMedlineWeb of Science Free via Creative Commons: Open access PDFEasy ReadData supplementRespond to this article Tweet Services Email to friendDownload to citation managerAdd article to BMJ portfolioRequest permission Citations Find similar articles in PubMedArticles by Alejandra CastanonArticles by Peter BrocklehurstArticles by Heather EvansArticles by Donald PeeblesArticles by Naveena SinghArticles by Patrick WalkerArticles by Julietta PatnickArticles by Peter SasieniCiting articles via Web of ScienceCiting articles via Scopus Social bookmarking Add to CiteULike CiteULikeAdd to Connotea ConnoteaAdd to Del.icio.us Del.icio.usAdd to Digg DiggAdd to Facebook FacebookAdd to Mendeley MendeleyAdd to Reddit RedditAdd to Del.icio.us TechnoratiAdd to Twitter TwitterAdd to StumbleUpon Stumbleupon Latest jobsUK jobsInternational jobsUK jobs AXESS LTD, EU MEDICAL ADVISER. (23 Aug 2012)SOLENT NHS TRUST SPECIALTY DOCTOR COMMUNITY SEXUAL AND REPRODUCTIVE HEALTHCARE (23 Aug 2012)Sessional roles for Doctors Scotland: (23 Aug 2012)UNIVERSITY OF LIVERPOOL SENIOR LECTURER (CLINICAL) IN NEONATOLOGY (23 Aug 2012) show me all jobs >> International jobs DOCTORS - ENJOY THE GREAT LIFESTYLE in Australia and New Zealand. SHO/ Registrar/ Consultant and GP openings. (6 Jul 2012)International Medical Recruitment - Medical Jobs in Australia and New Zealand (24 Aug 2012)Saudi Arabia - UAE - Kuwait On behalf of clients Shamco International Recruitment would like to invite applicants for various positions (24 Aug 2012)The Eureka Medical and Bougainvillea Clinic Consultants in General Internal Medicine and Paediatrics required in the British Virgin Islands (23 Aug 2012) show me all jobs >> Rapid responses Latest ResponsesMost responsesLatest Responses Re: Roy Simpson Published 24 August 2012

Why corporate power is a public health priority Published 24 August 2012

Cervical Intraepithelial Neoplasia and Pregnancy Management Published 24 August 2012

Incentives Published 24 August 2012

Re: Unhappy pills Published 24 August 2012

more Most responses Unhappy pills (11 responses)

Published 10 August 2012

Transcatheter aortic valve implantation (TAVI): risky and costly (8 responses)

Published 31 July 2012

We should not let families stop organ donation from their dead relatives (8 responses)

Published 7 August 2012

Diagnosis and management of cellulitis (8 responses)

Published 7 August 2012

Association between psychological distress and mortality: individual participant pooled analysis of 10 prospective cohort studies (7 responses)

Published 31 July 2012

more THIS WEEK'S POLL

Read related article

See previous polls

Recent blogs and podcastsBlogsPodcastsBlogs Domhnall MacAuley: Santa Claus and Lance Armstrong (24 Aug 2012)Tiago Villanueva: Does it matter where you do your medical training? (23 Aug 2012)James Drife: Doctors on the Fringe (22 Aug 2012)Steve Yentis: Infamous names in anaesthesia—part two (21 Aug 2012)Tessa Richards: Personal information empowers and its shift to the people makes sense (20 Aug 2012) more >> Podcasts Ecological public health (24 Aug 2012)Fighting the food giants (17 Aug 2012)Is the drug pipeline really drying up? (10 Aug 2012)Renal patient records (3 Aug 2012)Shift workers' health and assessing risk of violence (27 Jul 2012) more >> BMJ most popular Most sharedMost searchedMost shared Sample size calculations: should the emperor’s clothes be off the peg or made to measure? (804 views)The truth about sports drinks (696 views)When financial incentives do more good than harm: a checklist (650 views)Cochrane review finds no proved benefit in drug treatment for patients with mild hypertension (598 views)Myalgia while taking statins (589 views) Most searched Kathleen Hilditchguyattchronic liver diseasehow to read a paperFrance Follow BMJ On twitter.com/bmj_latestfacebook.com/bmjdotcomyoutube.com/user/BMJmedia Content Links Last 7 daysResearchEducationNewsCommentArchiveBlogsVideoPrint Issue My Account Email alertsActivate subscription Resources AuthorsReviewersBMA membersReadersSubscribersAdvertisers and sponsorsMedia Information Contact usFeedback BMJ About usEditorial staffAdvisersPoliciesComplaintsPartnershipsSubmit your paper Explore BMJ About BMJ GroupJunior Doctors: Agents for ChangeOlympics portalStudent BMJdoc2docPandemic FluBMJ Group BMJ Group Privacy and Cookie Policy Website T & Cs Revenue Sources HighWire Press Feedback Help © 2012 BMJ Publishing Group Ltd window.fbAsyncInit = function() {FB.init({appId: '154318714596620', status: true, cookie: true,xfbml: true});};(function() {var e = document.createElement('script'); e.async = true;e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js';document.getElementById('fb-root').appendChild(e);}());

View the original article here


This post was made using the Auto Blogging Software from WebMagnates.org This line will not appear when posts are made after activating the software to full version.

الخميس، 9 أغسطس 2012

Impact of age and sex on primary preventive treatment for cardiovascular disease in the West Midlands, UK: cross sectional study

Impact of age and sex on primary preventive treatment for cardiovascular disease in the West Midlands, UK: cross sectional study | BMJ

Menu

Search BMJ Group Search BMJ Group   Journals Jobs Education Decision support Quality improvement Community

BMJ Group

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients

About BMJ Group Customer Service Subscriptions & Sales Working for BMJ Group BMJ Media Centre BMJ Group Awards Advertising & Sponsorship Rights & Licensing Affinity & Society Publishing Online learning BMJ Learning High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications BMJ Masterclasses BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

BMJ Learning BMJ Portfolio BMJ Masterclasses Clinical Leadership Programme Diabetes Qualifications and Courses onExamination Decision support and clinical reference BMJ Evidence Centre

The BMJ Evidence Centre builds evidence into practice, to support improvements in the consistency and quality of health care.

Best Practice Clinical Evidence Evidence Updates Best Health Action Sets Informatica Systems Informatica Systems delivers performance management systems and innovative software solutions to primary care. Learn more

Audit + Contract + Health Checks FrontDesk BMJ Quality

The latest news, research, events, opinion and guidance related to quality and safety in health care.

The 2013 event will take place in London from 16th- 19th April 2013. Find out more

BMJ Quality BMJ Quality and Safety International Forum on Quality and Safety in Healthcare BMJ

The flagship general medical journal, published since 1840, updated daily online, weekly in print and on the iPad.

BMJ BMJ Journals

BMJ Journals division publishes over 40 journals across a broad range of specialties.

BMJ Journals studentBMJ

An international medical journal written for students by students.

Student BMJ Jobs BMJ Careers

BMJ Careers makes it easy for you to find the right job with the latest healthcare vacancies, upcoming careers fairs, advice on choosing the right specialty, pay and working conditions.

19-20 October 2012 at the Business Design Centre in Islington, London. Register here

BMJ Careers Jobs and vacancies at BMJ Group BMJ Careers Fair Community

Join the discussions on our community site doc2doc or our social pages

... by doctors, for doctors, for patients
We are open for entries!

doc2doc Follow BMJ Group on Twitter BMJ Group on Facebook BMJ Group Awards Subscribe My account

Update my details

Manage my emails

BMA Members Sign in Username: * Password: * Forgot your sign in details?BMA membersAthens or your organisation BMJ Helping doctors make better decisions Search bmj.com:   Advanced search Home Research Education News Comment Multimedia Specialties Archive Search all BMJ research articles:   From18401841184218431844184518461847184818491850185118521853185418551856185718581859186018611862186318641865186618671868186918701871187218731874187518761877187818791880188118821883188418851886188718881889189018911892189318941895189618971898189919001901190219031904190519061907190819091910191119121913191419151916191719181919192019211922192319241925192619271928192919301931193219331934193519361937193819391940194119421943194419451946194719481949195019511952195319541955195619571958195919601961196219631964196519661967196819691970197119721973197419751976197719781979198019811982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012JanFebMarAprMayJunJulAugSepOctNovDec To18401841184218431844184518461847184818491850185118521853185418551856185718581859186018611862186318641865186618671868186918701871187218731874187518761877187818791880188118821883188418851886188718881889189018911892189318941895189618971898189919001901190219031904190519061907190819091910191119121913191419151916191719181919192019211922192319241925192619271928192919301931193219331934193519361937193819391940194119421943194419451946194719481949195019511952195319541955195619571958195919601961196219631964196519661967196819691970197119721973197419751976197719781979198019811982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012JanFebMarAprMayJunJulAugSepOctNovDec Limit by AllResearchMethods and reporting Our online table of contents is updated at least twice each day. Read all articles published in the last 7 days. You can use bmj.com to help you with your continuing medical education. Find out about CME/CPD credits for BMJ articles Keep up to date with cardiology: Access the latest cardiovascular medicine resources from across BMJ Group. OPEN ACCESS: All research articles are freely available online, with no word limit. Find out more about the BMJ's open access policy. Submit your paper. Find out how study types differ in our How to read a paper section. Countdown to London 2012: BMJ Group's Olympics portal highlights latest Olympics and sports medicine-themed research, comment and learning

Research Impact of age and sex on primary preventive treatment for cardiovascular disease in the West Midlands, UK: cross sectional study BMJ 2012; 345 doi: 10.1136/bmj.e4535 (Published 12 July 2012) Cite this as: BMJ 2012;345:e4535 Drugs: cardiovascular system Epidemiologic studies Health promotion General practice / family medicine More topics

Hypertension Fewer topics

Article Related content Read responses (2) Article metrics J P Sheppard, research fellow1, S Singh, clinical research fellow1, K Fletcher, research fellow1, R J McManus, professor2, J Mant, professor3
1Primary Care Clinical Sciences, NIHR School for Primary Care Research, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
2Primary Care Health Sciences, NIHR School for Primary Care Research, University of Oxford, Oxford OX33 6GG, UK
3Primary Care Unit, University of Cambridge, Cambridge CB2 0SR, UKCorrespondence to: R J McManus richard.mcmanus{at}phc.ox.ac.ukAccepted 23 May 2012AbstractObjectives To establish the impact of age and sex on primary preventive treatment for cardiovascular disease in a typical primary care population.

Design Cross sectional study of anonymised patient records.

Participants All 41?250 records of patients aged =40 registered at 19 general practices in the West Midlands, United Kingdom, were extracted and analysed.

Main outcome measures Patients’ demographics, risk factors for cardiovascular disease (blood pressure, total cholesterol concentration), and prescriptions for primary preventive drugs were extracted from patients’ records. Patients were subdivided into five year age bands up to 85 (patients aged =85 were analysed as one group) and prescribing trends across the population were assessed by estimating the proportion of patients prescribed with antihypertensive drug or statin drug, or both, in each group.

Results Of the 41?250 records screened in this study, 36?679 (89%) patients did not have a history of cardiovascular disease and therefore could be considered for primary preventive treatment. The proportion receiving antihypertensive drugs increased with age (from 5% (378/6978) aged 40-44 to 57% (621/1092) aged =85) as did the proportion taking statins up to the age of 74 (from 3% (201/6978) aged 40-44 to 29% (675/2367) aged 70-74). In those aged 75 and above, the odds of a receiving prescription for a statin (relative to the 40-44 age group) decreased with every five year increment in age (odds ratio 12.9 (95% confidence interval 10.8 to 15.3) at age 75-79 to 5.7 (4.6 to 7.2) at age =85; P<0.001). There were no consistent differences in prescribing trends by sex.

Conclusions Previously described undertreatment of women in secondary prevention of cardiovascular disease was not observed for primary prevention. Low use of statins in older people highlights the need for a stronger evidence base and clearer guidelines for people aged over 75.

IntroductionCardiovascular disease remains the principal cause of death in the United Kingdom and around the world.1 Primary and secondary prevention of cardiovascular disease is a high priority, and this is reflected in current guidelines2 3 and national quality standards.4 These guidelines are supported by a large body of evidence that promotes the use of drugs to lower blood pressure and cholesterol concentration in patients at high risk of future cardiovascular disease events.5 6 7 8 9 10

It is well established that age and sex inequalities exist in secondary prevention of cardiovascular disease, particularly for cholesterol lowering treatment.11 12 13 14 15 16 17 Previous research has shown a “treatment-risk” paradox for secondary prevention, whereby patients become less likely to receive appropriate treatment the older they get.11 12 13 14 For example, Ko et al, showed that in addition to statin prescription rates being low throughout the secondary prevention population (75?617/396?077, 19%), the likelihood of statin treatment was 6% lower with each year increase in age.14

Health inequalities in secondary prevention by sex have also been described.15 16 Compared with men, women are less likely to be prescribed both antihypertensive (58% of women v 62% of men, P<0.001)15 and lipid lowering drugs (reported variously as 66% v 71%, P<0.00115; and 50% v 67%, P<0.0116). These disparities in statin prescription existed despite a higher proportion of women being above the recommended target cholesterol concentration.

The situation for primary prevention is less clear. To our knowledge, no previous studies have assessed the impact of age and sex on prescribing patterns in a primary preventive population. This might be because of the difficulty in defining who is eligible for such treatment when most patients have not been adequately screened to allow their absolute cardiovascular disease risk to be assessed.

Optimal screening strategies for identifying patients most at risk of developing cardiovascular disease have been studied extensively.18 19 20 21 It is unclear whether targeted treatment after such screening is more beneficial than blanket treatment for all those without existing cardiovascular disease with a “polypill” approach.22 In the UK, the Department of Health have opted to introduce a programme of “NHS health checks” for everyone aged between 40-74 without existing cardiovascular disease, aiming to reach all people within this age range over a period of five years.23 It is intended that people identified as having a high 10 year absolute risk of cardiovascular disease (that is, over 20%) will be provided with support for behaviour change and pharmacological treatment in accordance with relevant guidelines.3 23

Concerns about the viability and potential benefits of such a programme have been expressed.24 25 As one of the main aims of the programme is to reduce health inequalities,23 it is important to establish whether the age and sex inequalities observed in secondary prevention also exist in primary prevention. We assessed the impact of age and sex on prescription of antihypertensive drugs and statins for primary prevention of cardiovascular disease in a typical primary care population.

MethodsWe carried out a cross sectional retrospective study of primary care medical records. We obtained anonymised data from the electronic health records of all patients aged 40 and above registered at 19 general practices across the West Midlands. The practices were purposefully selected to represent different practice sizes and different levels of socioeconomic deprivation by using the indices of multiple deprivation score of the practice area. Relevant data were extracted with MIQUEST software.

Data queries were run from 17 October 2008 to 6 October 2009. Extracted information included demographic data, cardiovascular disease risk factors, and records of prescribed drugs. The presence of data for blood pressure or cholesterol concentration, or both, in the five years before the query date was defined as a non-zero value recorded in a value field linked to a relevant Read code for blood pressure or total cholesterol concentration. We made no attempts to impute missing data. Table 1 shows the proportion of patients with recorded cardiovascular disease risk factors?. We extracted data concerning prescription of drugs to lower blood pressure and cholesterol concentration in the 90 days before the query date.

View this table:View PopupView InlineTable 1 Characteristics of total population (by age group in years) potentially eligible for primary prevention treatment. Figures are numbers (percentages) unless stated otherwise

We excluded from our analysis any patients with a history of cardiovascular disease (stroke, transient ischaemic attack, myocardial infarction, coronary artery disease, heart failure, peripheral vascular disease). A history of cardiovascular disease was defined as any patient with a Read code for cardiovascular disease in their medical records. We assumed that, because of quality standards in the UK whereby general practitioners are paid based on accurate recording of information such as this,4 these data would be sufficiently accurate to identify the true secondary prevention population.

All patients without a history of cardiovascular disease were considered potentially eligible for primary prevention drugs. Strictly, only patients with a high absolute cardiovascular disease risk (=20%) and no other comorbidities should be considered for primary prevention treatment.3 26 Calculators used to establish this risk, however, have been validated only in patients aged up to 74,27 28 29 and no standardised method of estimating risk in elderly patients aged 75 and above has been established, though most people in this age group will have an absolute cardiovascular disease risk of =20%.30 To assess primary prevention trends in all eligible age groups, we included all patients aged over 40 with no history of cardiovascular disease, regardless of their calculated risk.

The proportion of patients receiving statins or antihypertensive drugs, or both, was estimated in five year age bands from 40 to 84. Those aged 85 and over were analysed in a single group because five year age bands above this age contained too few patients for reliable analyses between groups.

We used descriptive statistics to identify the proportion of patients with measured information on cardiovascular disease risk factors such as blood pressure, total cholesterol concentration, smoking status, and prescription for an antihypertensive drug or statin. We performed logistic regression analyses to examine associations between age group, sex, and prescription (statin and antihypertensive). Odds ratios were estimated to determine the change in likelihood of prescription of drug treatment per five year increase in age (with prescription rates in the first age group (aged 40-44) used as the reference category). All data are presented as means and standard deviation, odds ratios with 95% confidence interval, and percentages of the total primary prevention population (unless otherwise stated).

ResultsOf the 90?516 patients registered at participating practices, 41?250 matched our inclusion criteria (patients aged =40). Of these, 4571 (11%) had a record of existing cardiovascular disease, leaving 36?679 patients potentially eligible for primary preventive treatment. Table 1 shows that the proportion of patients with cardiovascular disease increased with age (from 1% (57/7035) at age 40-44 to 37% (632/1724) at age =85).

The proportion of patients with some specific risk factors for cardiovascular disease in the primary prevention population decreased with age: there were fewer men, fewer individuals with South Asian/Afro-Caribbean ethnicities, and fewer smokers (table 1). Recording of both blood pressure and cholesterol concentration improved with age, albeit from a much lower baseline for cholesterol. When recorded, mean blood pressure increased with age and mean cholesterol was stable (table 1).

The proportion of patients receiving antihypertensive drugs increased with age (from 5% (378/6978) aged 40-44 to 57% (621/1092) aged =85) (fig 1?). The likelihood of prescription of an antihypertensive drug increased with each five year increment in age up to =85 (from odds ratio 1.8 (95% confidence interval 1.6 to 2.0) at age 45-49 (P<0.001) to 25.8 (22.2 to 30.1) at age 80-84 (P<0.001); table 2?).

View larger version:In a new windowDownload as PowerPoint SlideFig 1 Proportion of patients prescribed antihypertensive drugs and mean blood pressure of treated and untreated patients

View this table:View PopupView InlineTable 2 Likelihood of prescription of statins and antihypertensive drugs per five year increase in age (reference category was prescription rates in those aged 40-44)

The proportion of patients taking statin drugs also increased with age up to 74 (from 3% (201/6978) aged 40-44 to 29% (675/2367) aged 70-74) (fig 2?). In those aged 75 and over, however, only 963/4254 (23%) were prescribed statins (fig 2?). The likelihood of prescription of a statin was consistently higher with each five year increment in age up to 74 (from 1.8 (1.5 to 2.1) at age 45-49 (P<0.001) to 13.6 (11.5 to 16.1) at age 70-74 (P<0.001); table 2). Thereafter, in those aged =75, the odds of receiving a statin prescription decreased with every five year increment in age (from 12.9 (10.8 to 15.3) at age 75-79 (P<0.001) to 5.7 (4.6 to 7.2) at age =85 (P<0.001)).

View larger version:In a new windowDownload as PowerPoint SlideFig 2 Proportion of patients prescribed cholesterol lowering drugs and mean cholesterol concentration of treated and untreated patients

The proportion of men and women prescribed antihypertensive drugs was similar in all age groups apart from those aged 65-69 and 75-79, in whom prescriptions were more common in women (39% (610/1562) in women v 34 % (454/1331) in men for ages 65-69; 55% (634/1152) v 48 % (367/757), respectively, for ages 75-79; fig 3?). Overall, women were 10% more likely to receive antihypertensive drugs than men (P<0.001). Statin prescriptions were more common in men than women in those aged under 60 (6% (663/11?078) in women v 8% (947/11?892) in men for ages 40-59) but higher in women aged over 75 (28% (537/1949) in women v 22% (272/1213) in men, for ages 75-84). Overall, men were more likely to receive statin prescriptions than women (odds ratio 1.1, 1.1 to 1.2; P<0.001).

View larger version:In a new windowDownload as PowerPoint SlideFig 3 Proportion of patients prescribed primary preventive drug treatment in each age group by sex

DiscussionSummary of findingsThis study assessed current rates of prescription of primary prevention across a typical primary care population with no previous history of cardiovascular disease. As expected, blood pressure increased with age but while antihypertensive treatment also increased, many older people did not receive blood pressure lowering drugs and most people of all ages were not prescribed statins. This was particularly an issue in the oldest age groups where, despite reasonable recording of risk factors, statins were prescribed in only a fraction of those eligible assuming an absolute cardiovascular disease risk of >20% for most of those aged over 75.30 This increasingly important cohort of older individuals has been largely ignored by current primary prevention programmes, which focus on people under the age of 75. As the population ages, both statins and antihypertensive drugs offer the prospect of further reducing mortality and cardiovascular disease events, but only if they are prescribed.10 31

Strengths and weaknesses of the studyIn this large study we used routine data from practices across the West Midlands and included all registered patients over the age of 40. For the purposes of this study, the West Midlands is representative of the national picture, having similar mortality rates in people aged =75 compared with the national picture (death rates in people aged 75-84 and in people aged =85 are 56.6 per 1000 and 152.7 per 1000, respectively, in England and Wales compared with 58.5 per 1000 and 157.6 per 1000 in the West Midlands).32 The advantage of using this cohort over data from the Health Survey for England33 is that the entire population from the study area was sampled and bias from differential response rates was not possible. In addition, we captured accurate data on all prescribed drugs over the preceding 90 days rather than having to rely on self reported accounts from participating patients, as was the case in the Health Survey for England.33

We included all patients in this analysis, regardless of their calculated cardiovascular risk. Given that age is the most significant factor in cardiovascular risk scores,22 30 if we had done the analysis taking account of risk, the association of older age with non-use of preventive drugs would have been more marked. We did not do this as the risk calculators have been less well validated for people over the age of 75,27 29 and true denominators would be difficult to establish as treatment with antihypertensive drugs and statins will lower calculated risk.

In estimating the proportion of patients receiving treatment, we could not account for contraindications to drug treatment, the general practitioner’s judgment in individual cases, or patients’ choice.34 In addition, we could not distinguish between people who had never been offered primary preventive treatment and those in whom drug treatment was stopped, perhaps because of side effects or because of increasing age or frailty.

Study findings in the context of previous researchThe “treatment-risk” paradox we observed, particularly for lipid lowering drugs, has been identified before in elderly patients eligible for secondary prevention.11 12 13 14 The evidence supporting prescription of antihypertensive drugs in elderly patients is relatively well established. The HYVET study showed that antihypertensive treatment in independently living patients over the age of 80 with or without previous cardiovascular disease reduces risk of cardiovascular events and increases life expectancy.31 Patients recruited to this trial were healthier than people of similar ages within the general population because of the strict exclusion criteria that restricted patients with multiple co-existing illnesses from participation.35 Nevertheless, antihypertensive drugs are generally considered safe and effective in elderly patients, as reflected in guidelines in which recommendations on prescription of antihypertensive drugs are not restricted by age.26

The evidence for use of statins in the elderly is less clear.36 The Heart Protection Study showed that treatment of people at high risk of cardiovascular disease of all ages (40-80) with simvastatin 40 mg results in a decreased risk of mortality from cardiovascular disease, coronary events, strokes, and revascularisations with no increased risk of mortality from non-cardiovascular disease or haemorrhagic stroke.10 This effect was independent of age. The MEGA trial found a 33% risk reduction for coronary heart disease with no increase in non-cardiovascular disease mortality or other adverse events, and this effect was independent of age up to 80.8 The ASCOT-LLA trial (in patients aged 40-79) found that statins reduce the risk of cardiovascular disease events and procedures (including fatal and non-fatal stroke),9 and this effect was again independent of age.37 The PROSPER trial, however, showed that while pravastatin given for three years reduced the risk of coronary disease in elderly individuals (aged 70-82), it had no effect on the risk of stroke.38

Despite evidence that supports the use of statins in patients up to the age of 80,8 9 10 37 38 our findings suggest that general practitioners are choosing to follow guidelines3 that recommend their use only up to age 74. Beyond 80, it is not clear whether statins are effective for primary prevention. This ambiguity exists not because of conflicting trial results, but because trials have not been conducted in this population.39 There is no evidence to suggest that prescribing statins in elderly patients causes any increased side effects or adverse effects. The JUPITER trial found that (in patients aged 50-97), although adverse events were increased in older patients, there was no significant difference in such events between those taking statins and those taking placebo.40 41

In the absence of evidence from trials, guidelines rely on expert opinion.3 Currently, while these guidelines note that statins are likely to be beneficial, they fall short of explicitly recommending them for the over 80s, and our findings suggest that general practitioners are not using them in most people of this age. Given the underlying risk associated with age30 42 and that the protective effects of primary prevention drugs can be realised within just one year,43 a case can be made for offering primary prevention to a larger proportion of people aged 80 and over than are currently receive it.

In contrast with previous research on secondary prevention15 16 we found minimal clinically significant differences in prescription rates between men and women. This is perhaps surprising given that at any age men are at greater risk of a cardiovascular disease event than women.30 42

Implications for policy, research, and clinical practiceIt is difficult to interpret whether the low use of preventive treatments (particularly statins) in older people reflects appropriate or inappropriate care. The non-use of these drugs might reflect a considered decision that has taken into account factors associated with age that might deter doctors from prescribing such as multiple comorbidity, polypharmacy, and cognitive decline as well as the patient’s choice. There is only limited evidence of effectiveness, for statins at least, in people over the age of 80. Nevertheless, there is a striking contrast between use of statins and use of antihypertensive drugs in older people, which does point to possible underuse of statins. To better understand the clinical implications of our findings, more research is needed to determine why general practitioners refrain from prescribing primary preventive treatment in elderly people, the attitudes of older people towards preventive drugs, and the costs and benefits of prescribing in this age group. These are important questions to answer. The number of people aged 80 and over is projected to rise rapidly,44 and greater use of these drugs might reduce disability and prolong healthy life expectancy in this age group.

Ultimately, evidence is needed to inform new guidelines that offer more precise recommendations on primary prevention for older people. In particular, consideration needs to be given to whether to continue to use an absolute risk based approach to guide treatment, whether there is a role for novel biomarkers to differentiate people who would benefit from treatment, or whether the optimal strategy might be to offer treatment to all people over a given age with fixed combination low dose multiple preventive drugs, otherwise known as the polypill approach.22 It has been estimated that this could reduce the incidence of cardiovascular disease events by up to 80%.22 The original polypill proposal suggested treating everyone over the age of 55, regardless of their absolute risk of cardiovascular disease.22 Use of this strategy in people aged =75 could be an appropriate place to start, with a simple drug regimen that could reduce absolute risk with few adverse effects.45

ConclusionsCurrent guidelines3 and screening strategies46 for primary prevention of cardiovascular disease focus on people aged 40-74. Our study suggests that this is having an effect on the care of elderly patients aged =75. With continuing advances in healthcare, the elderly population is increasing and people are living to an older age.44 They should therefore not be ignored by clinical trials and guidelines or overlooked in strategies for primary prevention of cardiovascular disease.

More research is needed to inform practice in primary prevention to deal with developing age inequalities and offer more specific advice about how best to treat elderly patients. Future research should test whether innovative treatment strategies, such as use of a polypill, could reverse these age inequalities in treatment of absolute risk of cardiovascular disease. There is a case for a simple trial of use of statins in people over the age of 80.

What is already known on this topicAntihypertensive drugs and statins are safe and effective treatments for absolute risk of cardiovascular disease

Age inequalities exist in prescription of statins for elderly patients with existing cardiovascular disease

What this study addsAge inequalities also exist in those eligible for primary preventive treatment

Prescribing trends for statins seem to closely follow guidelines, which do not offer clear guidance for elderly patients

NotesCite this as: BMJ 2012;345:e4535

FootnotesWe thank the following general practices for their participation and cooperation with this study; Greenridge Surgery, West Heath Surgery, Dudley Park Medical Centre, Selly Park Surgery, 112 Weoley Park Road Surgery, Sutton Park Surgery, Bellevue Medical Centre, Druids Heath Surgery, Jiggins Lane Medical Centre, River Brook Medical Centre, Bournville Surgery, 192 Charles Road Surgery, 75-77 Cotterills Lane Surgery, Mere Green Surgery, Parkfield Medical Centre, Arden Medical Centre, The Jacey Practice, Hampton Surgery, and Broadway Health Centre.

Contributors: JM and RJMcM had the original idea and gained the funding. KF was responsible for the data collection. JPS undertook the analyses and wrote the first draft with RJMcM and SS. All authors subsequently refined the manuscript and approved the final version. JM is guarantor.

Funding: This work forms part of a larger programme on stroke prevention in primary care supported by the National Institute for Health Research (RP-PG-0606-1153). JPS and SS are funded by the National Institute for Health Research Birmingham and Black Country Collaboration for Leadership in Applied Health Research and Care. RJMcM holds an NIHR career development fellowship. The views and opinions expressed are those of the authors and do not necessarily reflect those of the NHS, NIHR, or the Department of Health.

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Ethical approval: All data collection was approved by the Birmingham East North and Solihull research ethics committee in June 2008 (No 08/H1206/91).

Study sponsor: The University of Birmingham acted as the study sponsor. They were responsible for the overall conduct of the study and ensured the relevant contracts, insurance and approvals were in place prior to the start of the study. They had no active role in the study design, data collection, analysis or dissemination.

Data sharing: Proposals for data sharing should be sent to the corresponding author.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.

References?World Health Organization. Prevention of cardiovascular disease: guidelines for assessment and management of cardiovascular risk. WHO Press, 2007.?National Institute for Health and Clinical Excellence. Hypertension: clinical management of primary hypertension in adults. CG127, 2011.?National Institute for Health and Clinical Excellence. Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. CG067, 2008. www.nice.org.uk/CG067.?British Medical Association, NHS Employers. Quality and outcomes framework guidance for GMS contract 2009/10: delivering investment in general practice. EGUI05501, 2009.?Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HAW, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet2004;364:685-96.OpenUrlCrossRefMedlineWeb of Science?Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet2005;366:895-906.OpenUrlCrossRefMedlineWeb of Science?Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet1998;351:1755-62.OpenUrlCrossRefMedlineWeb of Science?Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet2006;368:1155-63.OpenUrlCrossRefMedline?Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet2003;361:1149-58.OpenUrlCrossRefMedlineWeb of Science?Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet2002;360:7-22.OpenUrlCrossRefMedlineWeb of Science?Lemaitre RN, Furberg CD, Newman AB, Hulley SB, Gordon DJ, Gottdiener JS, et al. Time trends in the use of cholesterol-lowering agents in older adults—the Cardiovascular Health Study. Arch Intern Med1998;158:1761-8.OpenUrlCrossRefMedlineWeb of Science?Whincup PH, Emberson JR, Lennon L, Walker M, Papacosta O, Thomson A. Low prevalence of lipid lowering drug use in older men with established coronary heart disease. Heart2002;88:25-9.OpenUrlFREE Full Text?Gnavi R, Migliardi A, Demaria M, Petrelli A, Caprioglio A, Costa G. Statins prescribing for the secondary prevention of ischaemic heart disease in Torino, Italy. A case of ageism and social inequalities. Eur J Public Health2007;17:492-6.OpenUrlFREE Full Text?Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients—the treatment-risk paradox. JAMA2004;291:1864-70.OpenUrlCrossRefMedlineWeb of Science?Driscoll A, Beauchamp A, Lyubomirsky G, Demos L, McNeil J, Tonkin A. Suboptimal management of cardiovascular risk factors in coronary heart disease patients in primary care occurs particularly in females. Intern Med J2011;41:730-6.OpenUrlCrossRefMedline?Vulic D, Lee BT, Dede J, Lopez VA, Wong ND. Extent of control of cardiovascular risk factors and adherence to recommended therapies in US multiethnic adults with coronary heart disease: from a 2005-2006 national survey. Am J Cardiovasc Drugs2010;10:109-14.OpenUrlCrossRefMedlineWeb of Science?De Ruijter W, de Waal MW, Gussekloo J, Assendelft WJ, Blom JW. Time trends in preventive drug treatment after myocardial infarction in older patients. Br J Gen Pract2010;60:47-9.OpenUrlCrossRefMedline?Marshall T. The use of cardiovascular risk factor information in practice databases: making the best of patient data. Br J Gen Pract2006;56:600-5.OpenUrlMedlineWeb of Science?Holt TA, Thorogood M, Griffiths F, Munday S, Stables D. Identifying individuals for primary cardiovascular disease prevention in UK general practice: priorities and resource implications. Br J Gen Pract2008;58:495-8.OpenUrlCrossRefMedline?Lawson KD, Fenwick EAL, Pell ACH, Pell JP. Comparison of mass and targeted screening strategies for cardiovascular risk: simulation of the effectiveness, cost-effectiveness and coverage using a cross-sectional survey of 3921 people. Heart2010;96:208-12.OpenUrlFREE Full Text?Chamnan P, Simmons RK, Khaw KT, Wareham NJ, Giffin SJ. Estimating the population impact of screening strategies for identifying and treating people at high risk of cardiovascular disease: modelling study. BMJ2010;340:c1693.OpenUrlFREE Full Text?Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ2003;326:1419-23.OpenUrlFREE Full Text?NHS Health Check Programme. Putting Prevention First—NHS Health Check: vascular risk assessment and management best practice guidance. NHS, 2009.?Khunti K, Walker N, Sattar N, Davies M. Unanswered questions over NHS health checks. BMJ2011;342:c6312.OpenUrl?Reckless JP. Primary prevention of cardiovascular disease. BMJ2011;342:d201.OpenUrlFREE Full Text?National Institute for Health and Clinical Excellence. Hypertension: management of hypertension in adults in primary care. CG034, 2006. www.nice.org.uk/CG034.?Anderson KM, Odell PM, Wilson PWF, Kannel WB. Cardiovascular-disease risk profiles. Am Heart J1991;121:293-8.OpenUrlCrossRefMedlineWeb of Science?Collins GS, Altman DG. An independent and external validation of QRISK2 cardiovascular disease risk score: a prospective open cohort study. BMJ2010;340:c2442.OpenUrlFREE Full Text?Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ2008;336:1475-82.OpenUrlFREE Full Text?Wood DA, Wray R, Poulter N, Williams B, Kirby M, Patel V. JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart2005;91(suppl 5):v1-52.OpenUrlFREE Full Text?Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu LS, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med2008;358:1887-98.OpenUrlCrossRefMedline?Office for National Statistics. Mortality statistics: deaths registered in England and Wales. 2010. Series DR 10-5-2012. www.ons.gov.uk/ons/publications/re-reference-tables.html?edition=tcm%3A77-230730.?Aresu M, Chaudhury M, Diment E, Fuller E, Gordon-Dseagu V, Gunning N, et al. Health Survey for England 2009. Vol 1: health and lifestyles. Health and Social Care Information Centre, 2010.?Aarabi M, Skinner J, Price CE, Jackson PR. Patients’ acceptance of antihypertensive therapy to prevent cardiovascular disease: a comparison between South Asians and Caucasians in the United Kingdom. Eur J Cardiovasc Prev Rehabil2008;15:59-66.OpenUrlCrossRefMedlineWeb of Science?Messerli FH, Sulicka J, Gryglewska B. Treatment of hypertension in the elderly. N Engl J Med2008;359:972-3.OpenUrlMedlineWeb of Science?Robinson JG. Lipid-lowering therapy for the primary prevention of cardiovascular disease in the elderly: opportunities and challenges. Drugs Aging2009;26:917-31.OpenUrlCrossRefMedlineWeb of Science?Collier DJ, Poulter NR, Dahlof B, Sever PS, Wedel H, Buch J, et al. Impact of atorvastatin among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm. J Hypertens2011;29:592-9.OpenUrlCrossRefMedlineWeb of Science?Shepherd J, Blauw GJ, Murphy MB, Bollen ELEM, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet2002;360:1623-30.OpenUrlCrossRefMedlineWeb of Science?Robinson JG, Bakris G, Torner J, Stone NJ, Wallace R. Is it time for a cardiovascular primary prevention trial in the elderly? Stroke2007;38:441-50.OpenUrlFREE Full Text?Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, et al. Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein. N Engl J Med2008;359:2195-207.OpenUrlCrossRefMedlineWeb of Science?Glynn RJ, Koenig W, Nordestgaard BG, Shepherd J, Ridker PM. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med2010;152:488-96.OpenUrlFREE Full Text?Rothwell PM, Coull AJ, Silver LE, Fairhead JF, Giles MF, Lovelock CE, et al. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet2005;366:1773-83.OpenUrlCrossRefMedlineWeb of Science?Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet2005;366:1267-78.OpenUrlCrossRefMedlineWeb of Science?Office for National Statistics. Mid-year populations estimates: aging, fastest increase in the “oldest old.” 2010. www.ons.gov.uk.?Yusuf S, Pais P, Afzal R, Xavier D, Teo K, Eikelboom J, et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet2009;373:1341-51.OpenUrlCrossRefMedlineWeb of Science?Department of Health. Putting prevention first. Vascular checks: risk assessment and management. Impact assessment. Central Office of Information, 2008. Free via Creative Commons: Open access PDFSection PDFEasy ReadPress releaseRespond to this article Tweet Services Email to friendDownload to citation managerAdd article to BMJ portfolioRequest permission Citations Find similar articles in PubMedArticles by J P SheppardArticles by S SinghArticles by K FletcherArticles by R J McManusArticles by J MantCiting articles via Web of ScienceCiting articles via Scopus Social bookmarking Add to CiteULike CiteULikeAdd to Connotea ConnoteaAdd to Del.icio.us Del.icio.usAdd to Digg DiggAdd to Facebook FacebookAdd to Mendeley MendeleyAdd to Reddit RedditAdd to Del.icio.us TechnoratiAdd to Twitter TwitterAdd to StumbleUpon Stumbleupon Latest jobsUK jobsInternational jobsUK jobs Greenbrook is a small, GP-led organisation in West London. We are looking for a GP (20 Jul 2012)Velindre NHS Trust Welsh Blood Service Medical Director Consultant Scale Full time (13 Jul 2012)EAMES JONES JUDGE HAWKINS EUROPEAN MEDICAL DIRECTOR ONCOLOGY (23 Jul 2012)University of Cambridge The Professorship of Nuclear Medicine (19 Jul 2012) show me all jobs >> International jobs DOCTORS - ENJOY THE GREAT LIFESTYLE in Australia and New Zealand. SHO/ Registrar/ Consultant and GP openings. (6 Jul 2012)JERUDONG PARK MEDICAL CENTRE MEDICAL SERVICES 1. GENERAL PRACTITIONER (2 Aug 2012)LEAD THE FUTURE OF HEALTHCARE JurongHealth is Singapore’s public healthcare cluster formed to facilitate the integration of services (2 Aug 2012)JURUDONG PARK MEDICAL CENTRE MEDICAL SERVICES 1. CONSULTANT OBSTETRICIAN AND GYNAECOLOGIST (2 Aug 2012) show me all jobs >> Rapid responses Latest ResponsesMost responsesLatest Responses Re: Will the revolution in genetics improve healthcare? Published 3 August 2012

Re: Proposed targets for new NHS commissioners receive lukewarm response Published 3 August 2012

Re: Should patients be able to control their own records? Published 3 August 2012

Re: Association between psychological distress and mortality: individual participant pooled analysis of 10 prospective cohort studies Published 3 August 2012

Re: Effectiveness of enhanced communication therapy in the first four months after stroke for aphasia and dysarthria: a randomised controlled trial Published 3 August 2012

more Most responses The truth about sports drinks (12 responses)

Published 19 July 2012

In praise of young doctors (11 responses)

Published 11 July 2012

Sanctity of life law has gone too far (6 responses)

Published 12 July 2012

Should we screen for type 2 diabetes: Yes (4 responses)

Published 9 July 2012

Does telemedicine deserve the green light? (4 responses)

Published 10 July 2012

more THIS WEEK'S POLL

Read related article

See previous polls

Recent blogs and podcastsBlogsBlogs Richard Smith: An open blog to Prime Minister David Cameron (3 Aug 2012)Olympic volunteer John Davies: Working with athletes (3 Aug 2012)Penny Campling: Thoughts on a healthcare culture—part 2 (3 Aug 2012)Desmond O’Neill: Bicycle helmets and the medical humanities (3 Aug 2012)John Davies: Treating casualties at the London 2012 aquatic centre (2 Aug 2012) more >> BMJ most popular Most sharedMost searchedMost shared The truth about sports drinks (768 views)Management of osteoarthritis of the knee (650 views)Treating prostate cancer (503 views)Association between psychological distress and mortality: individual participant pooled analysis of 10 prospective cohort studies (471 views)Necrotising fasciitis (407 views) Most searched Kathleen Hilditchguyattclinical governance and the drivehow to read a paper"surgical sieve" Follow BMJ On twitter.com/bmj_latestfacebook.com/bmjdotcomyoutube.com/user/BMJmedia Content Links Last 7 daysResearchEducationNewsCommentArchiveBlogsVideoPrint Issue My Account Email alertsActivate subscription Resources AuthorsReviewersBMA membersReadersSubscribersAdvertisers and sponsorsMedia Information Contact usFeedback BMJ About usEditorial staffAdvisersPoliciesComplaintsPartnershipsSubmit your paper Explore BMJ About BMJ GroupJunior Doctors: Agents for ChangeOlympics portalStudent BMJdoc2docPandemic FluBMJ Group BMJ Group Privacy policy Website T & Cs Revenue Sources Highwire Press Feedback Help © 2012 BMJ Publishing Group Ltd window.fbAsyncInit = function() {FB.init({appId: '154318714596620', status: true, cookie: true,xfbml: true});};(function() {var e = document.createElement('script'); e.async = true;e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js';document.getElementById('fb-root').appendChild(e);}());

View the original article here


This post was made using the Auto Blogging Software from WebMagnates.org This line will not appear when posts are made after activating the software to full version.